Contributors |
|
xv | |
Preface |
|
xvii | |
Acknowledgments |
|
xix | |
|
Chapter 1 Biological warfare agents: History and modern-day relevance |
|
|
1 | (12) |
|
|
History of biological warfare agents |
|
|
1 | (2) |
|
Biological warfare agents |
|
|
3 | (2) |
|
Characteristics of biological weapons |
|
|
5 | (1) |
|
Advantages and disadvantages of biological agents |
|
|
6 | (1) |
|
Characteristics of an ideal biological warfare agent |
|
|
6 | (1) |
|
Classification of biological warfare agents according to the Center for Disease Control |
|
|
7 | (1) |
|
Present-day relevance of the agents |
|
|
8 | (1) |
|
|
8 | (1) |
|
|
9 | (1) |
|
|
10 | (3) |
|
Chapter 2 Bacterial biological warfare agents |
|
|
13 | (20) |
|
|
|
|
13 | (4) |
|
|
17 | (1) |
|
Biological warfare agents as a preferred weapon of destruction |
|
|
18 | (1) |
|
Biological warfare agents |
|
|
18 | (1) |
|
Bacterial biological warfare agents are unique |
|
|
18 | (1) |
|
|
19 | (2) |
|
Bacterial biological warfare agents |
|
|
21 | (2) |
|
Lists of bacterial biological warfare agents |
|
|
21 | (2) |
|
Reason behind rising bacterial bioterrorism |
|
|
23 | (1) |
|
Identifying the signs of biological attack |
|
|
24 | (1) |
|
Detection techniques for bacterial biological warfare agents |
|
|
24 | (1) |
|
Establishment of bacterial biological weapon programs |
|
|
25 | (2) |
|
Biological warfare program of the USSR |
|
|
25 | (1) |
|
Japanese biological warfare program |
|
|
26 | (1) |
|
United States biological warfare program |
|
|
26 | (1) |
|
Iraq's biological warfare program |
|
|
27 | (1) |
|
Impact of bacterial bioweaponization for society |
|
|
27 | (1) |
|
|
27 | (1) |
|
|
28 | (5) |
|
Chapter 3 Toxins as biological warfare agents |
|
|
33 | (32) |
|
|
|
|
33 | (2) |
|
|
35 | (3) |
|
|
35 | (3) |
|
|
38 | (3) |
|
|
38 | (1) |
|
Staphylococcal enterotoxins |
|
|
39 | (1) |
|
Staphylococcal enterotoxin B |
|
|
40 | (1) |
|
|
41 | (4) |
|
Trichothecenes (T-2) toxin |
|
|
41 | (3) |
|
|
44 | (1) |
|
|
45 | (1) |
|
|
45 | (1) |
|
|
46 | (2) |
|
|
46 | (2) |
|
|
48 | (5) |
|
|
48 | (2) |
|
|
50 | (3) |
|
|
53 | (1) |
|
|
53 | (11) |
|
|
64 | (1) |
|
Chapter 4 Viral agents including threat from emerging viral infections |
|
|
65 | (18) |
|
|
|
|
65 | (2) |
|
Biological warfare agents as a means of terrorism |
|
|
67 | (2) |
|
Viruses as biological warfare agents |
|
|
69 | (1) |
|
|
70 | (1) |
|
Viral biological warfare agents |
|
|
71 | (4) |
|
|
72 | (1) |
|
|
72 | (1) |
|
|
73 | (1) |
|
|
73 | (1) |
|
|
74 | (1) |
|
|
74 | (1) |
|
Identification of signs of viral attack |
|
|
75 | (1) |
|
Detection techniques for viral biological warfare agents |
|
|
75 | (1) |
|
Impact of viral bioterrorism |
|
|
76 | (1) |
|
|
77 | (1) |
|
|
77 | (1) |
|
|
78 | (3) |
|
|
81 | (2) |
|
Chapter 5 Advance detection technologies for select biothreat agents |
|
|
83 | (20) |
|
|
|
|
|
83 | (1) |
|
Bio-detection technologies |
|
|
84 | (1) |
|
|
85 | (1) |
|
|
85 | (1) |
|
Immunochromatographic test (ICT) |
|
|
85 | (1) |
|
Lateral flow rapid strip test |
|
|
85 | (1) |
|
|
86 | (1) |
|
|
86 | (3) |
|
Polymerase chain reaction (PCR) |
|
|
87 | (1) |
|
|
87 | (1) |
|
Isothermal gene amplification assays |
|
|
88 | (1) |
|
Next-generation sequencing (NGS) technology |
|
|
89 | (1) |
|
|
89 | (1) |
|
Aerosol detection technologies |
|
|
90 | (1) |
|
|
90 | (1) |
|
|
91 | (1) |
|
Instrumental technologies |
|
|
91 | (2) |
|
|
91 | (2) |
|
|
93 | (1) |
|
|
93 | (1) |
|
Commercially available biodetectors |
|
|
93 | (5) |
|
|
98 | (1) |
|
|
99 | (4) |
|
Chapter 6 Microfluidics application for detection of biological warfare agents |
|
|
103 | (30) |
|
|
|
|
|
|
|
|
103 | (1) |
|
|
104 | (1) |
|
Pathogens involved in bioterrorism |
|
|
105 | (2) |
|
|
107 | (1) |
|
|
107 | (1) |
|
Available systems for bioterrorism |
|
|
108 | (2) |
|
|
108 | (1) |
|
|
109 | (1) |
|
Nucleic acid amplification and detection methods |
|
|
109 | (1) |
|
Bio-warfare agents monitoring |
|
|
110 | (1) |
|
|
110 | (1) |
|
Microfluidic applications in biodefense |
|
|
110 | (1) |
|
|
110 | (1) |
|
|
111 | (2) |
|
|
113 | (5) |
|
Continuous flow microfluidics |
|
|
114 | (1) |
|
|
115 | (3) |
|
Advanced digital microfluidic platforms |
|
|
118 | (1) |
|
Various available platforms for bioterrorism |
|
|
118 | (2) |
|
Nucleic acid-based microfluidic pathogen sensor |
|
|
120 | (2) |
|
Microfluidic cell-based pathogen sensing |
|
|
122 | (1) |
|
Microfluidics in combination with mass spectrometry |
|
|
123 | (1) |
|
Microfluidic pathogen detection systems-based antibody and aptamer sensor |
|
|
124 | (1) |
|
Microfluidic protein/enzyme based pathogen sensing |
|
|
125 | (1) |
|
Microfluidics in combination with fluorescence spectrometry |
|
|
126 | (1) |
|
Microfluidics in combination with electrochemistry |
|
|
126 | (1) |
|
|
127 | (1) |
|
|
128 | (3) |
|
|
131 | (2) |
|
Chapter 7 Collection, storage, and transportation of samples for offsite analysis |
|
|
133 | (18) |
|
|
|
|
|
|
133 | (3) |
|
|
136 | (1) |
|
|
137 | (6) |
|
Specimen collection procedures |
|
|
137 | (1) |
|
Collection of blood samples |
|
|
138 | (1) |
|
|
139 | (1) |
|
|
140 | (1) |
|
Saliva/buccal specimen collection |
|
|
140 | (1) |
|
Nail and hair sample collection |
|
|
141 | (2) |
|
|
143 | (3) |
|
Maintenance of storage systems |
|
|
145 | (1) |
|
Precautions to be taken before storage of specimens |
|
|
145 | (1) |
|
Transportation of collected samples |
|
|
146 | (1) |
|
|
147 | (1) |
|
|
147 | (1) |
|
|
147 | (4) |
|
Chapter 8 Medical management of diseases associated with biological warfare |
|
|
151 | (22) |
|
|
|
|
151 | (1) |
|
Treatment for bacteria BW agents |
|
|
152 | (9) |
|
|
152 | (2) |
|
|
154 | (1) |
|
|
155 | (1) |
|
|
156 | (2) |
|
|
158 | (1) |
|
|
159 | (2) |
|
Treatment for virus BW agents |
|
|
161 | (5) |
|
|
161 | (1) |
|
Crimean-Congo hemorrhagic fever |
|
|
162 | (1) |
|
|
163 | (1) |
|
Venezuelan equine encephalitis |
|
|
164 | (2) |
|
Treatment for toxins BW agents |
|
|
166 | (2) |
|
|
166 | (1) |
|
|
166 | (1) |
|
|
167 | (1) |
|
|
168 | (1) |
|
|
168 | (5) |
|
Chapter 9 Protective equipment for protection against biological warfare agents |
|
|
173 | (22) |
|
|
|
|
|
|
|
173 | (2) |
|
Classification of biological warfare agents and their symptoms |
|
|
175 | (1) |
|
Routes of exposure and modes of delivery |
|
|
175 | (2) |
|
Why there is need of protection? |
|
|
177 | (1) |
|
Principles of body and respiratory protection |
|
|
178 | (9) |
|
|
178 | (5) |
|
|
183 | (2) |
|
Protection through vaccine and antibiotics |
|
|
185 | (2) |
|
Materials used for the fabrication of IPEs |
|
|
187 | (1) |
|
State-of-the-art products available for protection |
|
|
187 | (1) |
|
Outlook, prospects, and challenges |
|
|
187 | (3) |
|
|
190 | (5) |
|
Chapter 10 Environmental sampling and bio-decontamination---Recent progress, challenges, and future direction |
|
|
195 | (14) |
|
|
|
Introduction and background |
|
|
195 | (1) |
|
Environmental bio-sampling |
|
|
196 | (3) |
|
Infrastructure decontamination |
|
|
199 | (4) |
|
|
203 | (1) |
|
Future research directions |
|
|
204 | (2) |
|
Conclusions and closing remarks |
|
|
206 | (1) |
|
|
206 | (3) |
|
Chapter 11 Biological and toxin warfare convention: Current status and future prospects |
|
|
209 | (8) |
|
|
|
209 | (1) |
|
|
210 | (1) |
|
The BWC, its expeditions, plights, and current status |
|
|
211 | (3) |
|
|
211 | (1) |
|
|
212 | (1) |
|
Lack of compliance and related verification |
|
|
212 | (1) |
|
Implementation challenges |
|
|
213 | (1) |
|
The future of the convention |
|
|
214 | (1) |
|
|
214 | (3) |
|
Chapter 12 Next generation agents (synthetic agents): Emerging threats and challenges in detection, protection, and decontamination |
|
|
217 | (40) |
|
|
|
|
|
|
Potential biological weapons and warfare agents |
|
|
217 | (4) |
|
A brief history of biological warfare |
|
|
221 | (3) |
|
Emergence of next generation biological weapons |
|
|
224 | (1) |
|
Binary biological weapons |
|
|
224 | (1) |
|
|
224 | (1) |
|
|
224 | (1) |
|
Gene therapy based bioweapons |
|
|
225 | (1) |
|
|
225 | (1) |
|
|
225 | (1) |
|
Synthetic biology assisted whole genome synthesis of bacterial clones and bacteriophages |
|
|
225 | (3) |
|
Synthesis of bacteriophage φX174 |
|
|
226 | (1) |
|
Synthesis bacteriophage T7 genome by refactoring process |
|
|
226 | (1) |
|
Synthesis of M. genitalium and M. mycoides clones using minimal genome content |
|
|
226 | (2) |
|
Synthetic biology assisted whole genome synthesis of native or chimeric viruses |
|
|
228 | (3) |
|
Synthesis of the 1918 Spanish flu virus |
|
|
229 | (1) |
|
|
229 | (1) |
|
Synthesis of human endogenous retrovirus |
|
|
230 | (1) |
|
|
230 | (1) |
|
Synthesis of SARS-like coronavirus |
|
|
230 | (1) |
|
In vitro packaging of viral genomes |
|
|
231 | (2) |
|
Mechanism for dsRNA viral genome packaging |
|
|
231 | (1) |
|
Mechanism for dsDNA viral genome packaging |
|
|
232 | (1) |
|
Examples of in vitro packaged viral genomes |
|
|
232 | (1) |
|
Biowarfare agent detection: Methods and challenges |
|
|
233 | (4) |
|
Microbiological culturing |
|
|
234 | (1) |
|
|
234 | (1) |
|
Cellular fatty acid based profiling |
|
|
234 | (1) |
|
|
234 | (1) |
|
|
235 | (1) |
|
Next generation sequencing |
|
|
236 | (1) |
|
|
236 | (1) |
|
Biophysical detector systems |
|
|
237 | (1) |
|
Protection against next generation biological agents: Methods and challenges |
|
|
237 | (8) |
|
Chimeric or designer viruses as candidates to study disease pathogenesis |
|
|
239 | (2) |
|
Chimeric viruses as important vaccines candidates |
|
|
241 | (4) |
|
Decontamination procedures: Methods and challenges |
|
|
245 | (1) |
|
|
246 | (1) |
|
|
247 | (10) |
|
Chapter 13 Genome information of BW agents and their application in biodefence |
|
|
257 | (16) |
|
|
|
|
257 | (1) |
|
Genome information of BWAs |
|
|
258 | (7) |
|
|
258 | (2) |
|
|
260 | (4) |
|
|
264 | (1) |
|
Application of genomic information in biodefense |
|
|
265 | (2) |
|
Design and development of vaccines against BW agents |
|
|
265 | (1) |
|
Understanding of virulence and resistance patterns of BW agents |
|
|
266 | (1) |
|
Environmental detection of BW agents |
|
|
266 | (1) |
|
Identification and characterization of potential BW agents |
|
|
266 | (1) |
|
Design and development of new chemical entity (NCE) against BW agents |
|
|
266 | (1) |
|
Understanding of infectious disease process |
|
|
267 | (1) |
|
|
267 | (1) |
|
|
267 | (4) |
|
|
271 | (2) |
|
Chapter 14 Planning for protection of civilians against bioterrorism |
|
|
273 | (6) |
|
|
|
273 | (1) |
|
The need for the "Bio-shield" system |
|
|
274 | (1) |
|
Future dangers in bioterrorism |
|
|
274 | (1) |
|
Use of CRISPR technology/Cas system |
|
|
275 | (1) |
|
Existence of biosurveillance |
|
|
275 | (1) |
|
Creation of novel vaccines |
|
|
276 | (1) |
|
Potential threats in force |
|
|
276 | (1) |
|
|
276 | (1) |
|
|
276 | (1) |
|
Toward improvement in vaccine production |
|
|
277 | (1) |
|
Biodefense mechanism and doctrine |
|
|
277 | (1) |
|
|
277 | (1) |
|
|
278 | (1) |
Index |
|
279 | |